Arcellx

Gilead and Kites exhibit booth at ASH 2025

Biotech

ASH: Anito-cel strengthens potential as Kite preps for launch

The Arcellx-partnered therapy achieved a 96% overall response rate at the 15.9-month mark, with 74% of patients’ cancer disappearing completely.

Darren Incorvaia Dec 7, 2025 11:52am

Legend

Fierce Pharma

J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T

Nov 12, 2025 11:36am

Rendering of an immune cell

ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma

Nov 5, 2024 3:08pm

Graphic image of a body shaded in black with drawn clouds around their head Dark blue background

NIH to invest another $515M over 4 years for long COVID research

Feb 15, 2024 10:57am

market busy fresh fruit buy crowd

Gilead hands Arcellx $285M to expand BCMA cell therapy deal

Nov 15, 2023 10:00am

Go sign green light

FDA lifts hold on Gilead's CAR-T as Arcellx sheds light on death

Aug 15, 2023 8:32am